1. Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial. (September 2020) Authors: Loomba, Rohit; Morgan, Erin; Watts, Lynnetta; Xia, Shuting; Hannan, Lisa A; Geary, Richard S; Baker, Brenda F; Bhanot, Sanjay Journal: Lancet gastroenterology and hepatology Issue: Volume 5:Number 9(2020) Page Start: 829 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗